Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Pre-IPOs
Unlock full access to global stock IPOs
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
Just been doing some research on healthcare sector investing, and I think I've found some solid options worth sharing. The thing about healthcare is it's genuinely recession-resistant. People need medical services and pharmaceuticals regardless of what's happening in the broader economy, which makes it a pretty smart defensive play.
When you're looking at the best biotech mutual funds specifically, mutual funds actually give you something individual stock picking doesn't - built-in diversification plus professional management. I've been looking at three funds that all have Strong Buy ratings from Zacks, and the numbers are pretty compelling.
First up is Franklin Strategic Biotechnology Discovery Fund (FBDIX). This one focuses on biotech companies and discovery research firms, with some flexibility to invest in other securities too. The three-year annualized returns sit at 20.9%, which is solid. As of last summer, they were holding 77 different positions with about 7.5% in Gilead Sciences. That kind of concentration in a single holding isn't huge, which I appreciate.
Then there's Fidelity Select Biotechnology (FBIOX). These guys use fundamental analysis to pick stocks in the biotech space - looking at company financials, industry position, market conditions, all the standard stuff. The three-year returns come in at 15.1% with a 0.63% expense ratio. That expense ratio is reasonable for an actively managed fund.
The third one, Fidelity Advisor Health Care Fund (FACTX), is slightly broader - it covers the whole healthcare sector, not just biotech. They've had five-year annualized returns of 5.6%. Edward Yoon has been managing this one since 2008, so there's some continuity there.
If you're trying to get exposure to healthcare without picking individual stocks, these best biotech mutual funds and healthcare funds give you that professional oversight. The performance data speaks for itself, especially FBDIX's recent run. Obviously do your own research and consider your risk tolerance, but this sector definitely deserves attention in a balanced portfolio.